Virios Therapeutics, Inc.
NASDAQ: VIRI0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Gregory Duncan
- Employees
- 4
- Headquarters
- Alpharetta, United States
- IPO year
- 2020
- Market cap
- $206.5K
- Website
- https://www.virios.com
Loading VIRI…
Loading profile data…Frequently asked questions about VIRI
What does Virios Therapeutics, Inc. (VIRI) do?
Virios Therapeutics, Inc. is a biotechnology firm in its development phase, dedicated to pioneering antiviral treatments for conditions that arise from an unusual immune response triggered by viral infections. Its primary investigational compound, IMC-1, is a precisely formulated blend of famciclovir and celecoxib, currently being developed to a...
Where does VIRI trade?
Virios Therapeutics, Inc. (VIRI) trades on the NASDAQ Capital Market.
What sector is VIRI in?
Virios Therapeutics, Inc. (VIRI) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Virios Therapeutics, Inc.?
Gregory Duncan is the chief executive officer of Virios Therapeutics, Inc. (VIRI).
Where is Virios Therapeutics, Inc. headquartered?
Virios Therapeutics, Inc. is headquartered in United States.
Does VIRI pay a dividend?
Virios Therapeutics, Inc. (VIRI) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did VIRI go public?
Virios Therapeutics, Inc. (VIRI) completed its initial public offering in 2020.